SMPD3

Across TCGA pan-cancer cohorts, SMPD3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMPD3 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SMPD3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SMPD3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and GBM are the cancer types where SMPD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.630	0.420	.001	51	view →
UCEC	DFS	Quartile	All	0.969	0.795	.014	20	view →
GBM	DFS	Tertile	All	0.923	0.598	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SMPD3–PDAC (OS)

Open the PDAC breakdown →